The estimated Net Worth of Jay Barth is at least $4.91 Milion dollars as of 30 September 2020. Jay Barth owns over 4,064 units of Amicus Therapeutics Inc stock worth over $1,885,110 and over the last 11 years he sold FOLD stock worth over $928,810. In addition, he makes $2,092,240 as Chief Medical Officer at Amicus Therapeutics Inc.
Jay has made over 24 trades of the Amicus Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 4,064 units of FOLD stock worth $9,307 on 30 September 2020.
The largest trade he's ever made was exercising 243,098 units of Amicus Therapeutics Inc stock on 7 July 2020 worth over $2,421,256. On average, Jay trades about 16,426 units every 35 days since 2014. As of 30 September 2020 he still owns at least 167,268 units of Amicus Therapeutics Inc stock.
You can see the complete history of Jay Barth stock trades at the bottom of the page.
Dr. Jay A. Barth M.D. serves as Chief Medical Officer of the Company. Prior to joining Amicus, Dr. Barth held roles of increasing responsibility at PTC Therapeutics from 2009 to 2014. He most recently served as PTC Therapeutics’ Senior Vice President, Clinical Development. Previously Dr. Barth served as Executive Director of Clinical Research at Merck; as Vice President, Clinical Research and Medical Affairs at Altana Pharma US, Inc.; and as Senior Director, Global Head of Gastroenterology Clinical Research at Eisai Medical Research Inc. Dr. Barth received a B.A. from Columbia University and an M.D. from the University of Pennsylvania School Of Medicine.
As the Chief Medical Officer of Amicus Therapeutics Inc, the total compensation of Jay Barth at Amicus Therapeutics Inc is $2,092,240. There are 5 executives at Amicus Therapeutics Inc getting paid more, with John Crowley having the highest compensation of $9,852,660.
Jay Barth is 56, he's been the Chief Medical Officer of Amicus Therapeutics Inc since 2014. There are 9 older and 11 younger executives at Amicus Therapeutics Inc. The oldest executive at Amicus Therapeutics Inc is Robert Essner, 72, who is the Independent Director.
Jay's mailing address filed with the SEC is C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY, NJ, 08512.
Over the last 17 years, insiders at Amicus Therapeutics Inc have traded over $306,740,337 worth of Amicus Therapeutics Inc stock and bought 23,821,602 units worth $176,323,212 . The most active insiders traders include Advisors Llcperceptive Life..., Peter J Barris a Plc Gsk. On average, Amicus Therapeutics Inc executives and independent directors trade stock every 10 days with the average trade being worth of $830,419. The most recent stock trade was executed by Bradley L Campbell on 3 September 2024, trading 7,500 units of FOLD stock currently worth $64,575.
amicus therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. we have a unique set of platform technologies and medicines in development for patients living with the lysosomal storage disorders fabry disease and pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. the needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. our amicus footprint spans 27 countries including our g
Amicus Therapeutics Inc executives and other stock owners filed with the SEC include: